ADCs targeting tumor-specific antigens, such as tissue factor (tisotumab vedotin) and HER2 (T-DXd), have also demonstrated clinical benefit in heavily pretreated patients [20, 29]. This evidence concerns the gene ERBB2 and neoplasm.